News

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

Revenue hit $3.3 billion with guidance raised on strong newer product growth.

Sionna said on Monday that its mid-stage trial of SION-719 in 15 adults with cystic fibrosis already taking Vertex’s Trikafta failed to meet its main goal.

The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.

Sionna's disappointing trial removes an immediate competitive threat to the franchise generating most of Vertex's revenue.

Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a setback for a key cystic fibrosis competitor together highlight Vertex’s efforts to broaden its pipeline while easing pressure on its core franchise. We’ll now examine how...

Shares of Tenax Therapeutics and Sionna Therapeutics tumbled Monday after the biotechs revealed separate late-stage trial failures. Tenax stock fell nearly 90% after a Phase 3 trial of its experimental heart-failure pill failed to help patients walk farther than those on a placebo.

Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment.

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

New data show a single dose of AbCellera’s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes.

This risk is weighing on the stock.

Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.

AbCellera Biologics Inc (ABCL) advances ABCL-635 with early phase 2 completion and secures over $110 million in new T-cell engager deals, despite a wider net loss and revenue decline.

AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. President and Chief Executive Officer Dr. Carl Hansen said enrol

Vertex Pharmaceuticals (VRTX) remains well positioned heading into the second half of 2026 as severa

Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength

Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.

CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.

Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.

Moby summary of Vertex Pharmaceuticals Incorporated's Q2 2026 earnings call

Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.

Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...

Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price that leans expensive rather than clearly cheap. Crinetics Pharmaceuticals has returned about 384% over the past 3 years, which puts recent enthusiasm for the stock firmly in focus for anyone thinking about upside from here. Vertex Pharmaceuticals' agreement to acquire Crinetics and the regulatory progress for atumelnant can support high...

Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.

Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX. Chief Executive Officer and President Reshma Kewalra

Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.

Wall Street futures pointed moderately higher pre-bell Monday after President Donald Trump, over the